Suppr超能文献

盲人“看”大象——脂肪肝疾病的多面性。

The blind men 'see' the elephant-the many faces of fatty liver disease.

作者信息

Sanal Madhusudana Girija

机构信息

Special Center for Molecular Medicine, Jawaharlal Nehru University, New Delhi 110067, India.

出版信息

World J Gastroenterol. 2008 Feb 14;14(6):831-44. doi: 10.3748/wjg.14.831.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a group of diseases with excess fat in liver in the absence of a poorly defined limit of alcohol consumption. Most common variety, a universal public health problem, is associated with insulin resistance caused by a host of genetic and epigenetic defects modulated by life style and environmental factors. In fact the term NAFLD is loose to incorporate so many etiologies except alcoholism and few other etiologies, presenting as fat in liver. However as a sign fatty liver is very important in predicting the risk of diabetes, cardiovascular disease, stroke, cirrhosis and cancer. Abnormal fat accumulation can result from several defects in nuclear receptors associated with lipid sensing, synthesis and oxidation like LXR, FXR, SREBP, ChREBP and PPAR; defects in the lipid influx-efflux channels, insulin signaling, proteins involved in fatty acid catabolism, defects in adipose tissue development and function, inappropriate nutrition and finally defects in neural regulatory mechanisms. The progress of the disease is determined by the basic defects which results in fat accumulation, an individual's immunological response to the accumulated fat and its derivatives and the oxidant stress response. Congregation of unrelated genetic defects under same diagnosis 'NAFLD' can result in inefficient patient management. Further studies are required to understand the molecular basis of fatty liver to enable a personalized management of diseases presenting as fatty liver in the absence of alcohol abuse.

摘要

非酒精性脂肪性肝病(NAFLD)是一组在酒精摄入量未明确界定的情况下肝脏脂肪过多的疾病。最常见的类型是一个普遍的公共卫生问题,与由多种遗传和表观遗传缺陷引起的胰岛素抵抗有关,这些缺陷受生活方式和环境因素调节。事实上,NAFLD这个术语很宽泛,涵盖了除酗酒和其他少数病因之外的众多病因,表现为肝脏脂肪堆积。然而,作为一种体征,脂肪肝在预测糖尿病、心血管疾病、中风、肝硬化和癌症风险方面非常重要。异常脂肪堆积可能源于与脂质感知、合成和氧化相关的核受体的多种缺陷,如肝X受体(LXR)、法尼酯X受体(FXR)、固醇调节元件结合蛋白(SREBP)、碳水化合物反应元件结合蛋白(ChREBP)和过氧化物酶体增殖物激活受体(PPAR);脂质流入-流出通道缺陷、胰岛素信号传导、参与脂肪酸分解代谢的蛋白质、脂肪组织发育和功能缺陷、营养不当,以及最终的神经调节机制缺陷。疾病的进展取决于导致脂肪堆积的基本缺陷、个体对堆积脂肪及其衍生物的免疫反应以及氧化应激反应。在同一诊断“NAFLD”下聚集不相关的遗传缺陷可能导致患者管理效率低下。需要进一步研究以了解脂肪肝的分子基础,从而能够在无酒精滥用的情况下对表现为脂肪肝的疾病进行个性化管理。

相似文献

1
The blind men 'see' the elephant-the many faces of fatty liver disease.
World J Gastroenterol. 2008 Feb 14;14(6):831-44. doi: 10.3748/wjg.14.831.
2
Nonalcoholic fatty liver disease: the concept and confusion.
Minerva Gastroenterol Dietol. 2011 Dec;57(4):419-26.
3
Insulin resistance in nonalcoholic fatty liver disease.
Curr Pharm Des. 2010 Jun;16(17):1941-51. doi: 10.2174/138161210791208875.
4
Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.
World J Gastroenterol. 2007 Jul 14;13(26):3540-53. doi: 10.3748/wjg.v13.i26.3540.
5
Effects of ethanol on lipid metabolism.
J Lipid Res. 1979 Mar;20(3):289-315.
6
Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
Gastroenterology. 2012 Apr;142(4):711-725.e6. doi: 10.1053/j.gastro.2012.02.003. Epub 2012 Feb 8.
7
Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk?
Endocr Metab Immune Disord Drug Targets. 2008 Dec;8(4):301-7. doi: 10.2174/187153008786848268.
8
Fatty liver: role of inflammation and fatty acid nutrition.
Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):265-71. doi: 10.1016/j.plefa.2010.02.012. Epub 2010 Mar 2.
9
Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Free Radic Biol Med. 2013 Dec;65:952-968. doi: 10.1016/j.freeradbiomed.2013.08.174. Epub 2013 Aug 29.
10
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD).
Prog Lipid Res. 2009 Jan;48(1):1-26. doi: 10.1016/j.plipres.2008.08.001. Epub 2008 Sep 9.

引用本文的文献

2
Fibrosis and hepatic regeneration mechanism.
Transl Gastroenterol Hepatol. 2022 Jan 25;7:9. doi: 10.21037/tgh.2020.02.21. eCollection 2022.
3
Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.
Ann Gastroenterol. 2017;30(2):209-216. doi: 10.20524/aog.2016.0107. Epub 2016 Dec 1.
4
Management of immunosuppressant agents following liver transplantation: Less is more.
World J Hepatol. 2016 Jan 28;8(3):148-61. doi: 10.4254/wjh.v8.i3.148.
5
Angiogenesis: a phenomenon which aggravates chronic liver disease progression.
Hepatol Int. 2013 Mar;7(1):4-12. doi: 10.1007/s12072-012-9391-2. Epub 2012 Jul 26.
6
Angiogenesis and liver fibrosis.
World J Hepatol. 2015 Mar 27;7(3):377-91. doi: 10.4254/wjh.v7.i3.377.
7
Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?
World J Gastroenterol. 2015 Mar 21;21(11):3223-31. doi: 10.3748/wjg.v21.i11.3223.
9
Insulin resistance in the liver: deficiency or excess of insulin?
Cell Cycle. 2014;13(16):2494-500. doi: 10.4161/15384101.2014.947750.
10
Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.
Lipids Health Dis. 2014 Nov 18;13:173. doi: 10.1186/1476-511X-13-173.

本文引用的文献

2
A novel acetyl-CoA carboxylase inhibitor reduces de novo fatty acid synthesis in HepG2 cells and rat primary hepatocytes.
Arch Biochem Biophys. 2007 Dec 1;468(1):44-8. doi: 10.1016/j.abb.2007.09.012. Epub 2007 Sep 25.
4
Liver: an alarm for the heart?
Liver Int. 2007 Sep;27(7):891-4. doi: 10.1111/j.1478-3231.2007.01531.x.
5
Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease.
World J Gastroenterol. 2007 Aug 21;13(31):4242-8. doi: 10.3748/wjg.v13.i31.4242.
6
7
Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma.
Gastroenterology. 2007 May;132(5):1955-67. doi: 10.1053/j.gastro.2007.03.039. Epub 2007 Mar 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验